
SRPT
Healthcare · Biotechnology · $1.72B market cap
$16.07+0.06 (+0.4%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -157.0% over 90 days · 30-day revisions 1 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | 0.17 | -0.10 | -158.8% |
| Aug 5, 2026 | After the close | 0.34 | 0.42 | +23.5% |
| May 6, 2026 | After the close | 1.05 | 3.16 | +201.0% |
| Mar 3, 2026 | Time not confirmed | -1.05 | -3.58 | -241.0% |
| Nov 3, 2025 | After the close | -0.37 | -0.13 | +64.9% |
| Aug 6, 2025 | After the close | 1.16 | 2.02 | +74.1% |
| May 6, 2025 | After the close | -0.65 | -3.42 | -426.2% |
| Feb 26, 2025 | Before the open | 2.06 | 1.90 | -7.8% |
| Nov 6, 2024 | After the close | 0.37 | 0.62 | +67.6% |
| Aug 7, 2024 | After the close | 0.47 | 0.44 | -6.4% |
| May 1, 2024 | After the close | 0.41 | 0.73 | +78.0% |
| Feb 28, 2024 | After the close | 0.01 | 0.47 | +4600.0% |
| Nov 1, 2023 | After the close | -0.49 | 0.37 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53…
| +175.5% |
| Aug 2, 2023 | After the close | -1.00 | -0.85 | +15.0% |
| May 2, 2023 | After the close | -0.83 | -0.97 | -16.9% |
| Feb 28, 2023 | After the close | -1.35 | -1.24 | +8.1% |
| Nov 2, 2022 | After the close | -0.74 | -0.80 | -8.1% |
| Aug 2, 2022 | After the close | -0.60 | -1.18 | -96.7% |
| May 4, 2022 | After the close | -1.03 | -0.56 | +45.6% |
| Mar 1, 2022 | After the close | -1.13 | -1.42 | -25.7% |
| Nov 3, 2021 | After the close | -1.52 | -0.19 | +87.5% |
| Aug 4, 2021 | After the close | -1.29 | -1.52 | -17.8% |
| May 5, 2021 | After the close | -1.57 | -1.54 | +1.9% |
| Mar 1, 2021 | After the close | -1.78 | -2.40 | -34.8% |
| Nov 5, 2020 | After the close | -1.40 | -1.42 | -1.4% |
| Aug 5, 2020 | After the close | -1.31 | -1.51 | -15.3% |
| May 6, 2020 | After the close | -1.88 | -0.23 | +87.8% |
| Feb 26, 2020 | After the close | -1.27 | -1.57 | -23.6% |
| Nov 7, 2019 | After the close | -0.92 | -1.14 | -23.9% |
| Aug 7, 2019 | After the close | -0.77 | -0.83 | -7.8% |
| May 8, 2019 | After the close | -0.81 | -0.75 | +7.4% |
| Feb 27, 2019 | After the close | -1.02 | -2.05 | -101.0% |
| Oct 24, 2018 | After the close | -0.49 | -0.56 | -14.3% |
| Aug 8, 2018 | After the close | -0.33 | -0.43 | -30.3% |
| May 3, 2018 | After the close | -0.24 | -0.28 | -16.7% |
| Mar 1, 2018 | After the close | -0.32 | -0.37 | -15.6% |